Cancer Stem Cell News Volume 3.28 | Jul 23 2014

Cancer Stem Cell News 3.28 July 23, 2014

Cancer Stem Cell News

     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cancer Stem Cell News on Twitter

Increased Notch Signaling Inhibits Anoikis and Stimulates Proliferation of Prostate Luminal Epithelial Cells
Scientists show that constitutive expression of Notch1 intracellular domain impairs secretory function of mouse prostate luminal cells, suppresses anoikis of luminal epithelial cells by augmenting NF-κB activity independent of Hes1, stimulates luminal cell proliferation by potentiating PI3K-AKT signalling, and rescues the capacities of the putative prostate luminal progenitors for unipotent differentiation in vivo and short-term self-renewal in vitro. [Nat Commun] Abstract
Culture Human Glioma-Derived Tumorspheres with NeuroCult™ - View Publications

PUBLICATIONS (Ranked by impact factor of the journal)
TLR9 is Critical for Glioma Stem Cell Maintenance and Targeting
Scientists show that the Toll-like receptor TLR9 is elevated in glioma stem-like cells (GSC) where it contributes to glioma growth. TLR9 overexpression is regulated by STAT3 which was required for GSC maintenance. [Cancer Res] Abstract

Elimination of Quiescent/Slow-Proliferating Cancer Stem Cells by Bcl-XL Inhibition in Non-Small Cell Lung Cancer
Scientists found that Bcl-XL is constantly expressed by lung cancer stem cells (LCSCs) and has a prominent role in regulating LCSC survival. [Cell Death Differ] Abstract

Knockdown of PTHR1 in Osteosarcoma Cells Decreases Invasion and Growth and Increases Tumor Differentiation In Vivo
Researchers used shRNA to reduce parathyroid hormone (PTH)/PTH-related protein receptor (PTHR1) expression. This only mildly inhibited proliferation in vitro, but markedly reduced invasion through collagen and reduced expression of RANK ligand. Administration of PTH(1-34) did not stimulate osteosarcoma proliferation in vivo but, strikingly, PTHR1 knockdown resulted in a profound growth inhibition and increased differentiation/mineralization of the tumors. [Oncogene] Abstract

DAB2IP Regulates Cancer Stem Cell Phenotypes through Modulating Stem Cell Factor Receptor and ZEB1
Scientists demonstrate that the loss of DAB2IP, a novel Ras-GTPase activating protein frequently found in many cancer types, is associated with cancer stem cell properties. [Oncogene] Abstract

NPPB Is a Novel Candidate Biomarker Expressed by Cancer-Associated Fibroblasts In Epithelial Ovarian Cancer
Researchers report establishing in vitro and in vivo models of cancer-associated fibroblasts (CAFs) in ovarian cancer development. Normal ovarian fibroblasts and mesenchymal stem cells cultured in the presence of epithelial ovarian cancers (EOC) cells acquired a CAF-like phenotype, and promoted EOC cell migration in vitro. [Int J Cancer] Abstract

FZD7 Drives In Vitro Aggressiveness in Stem-A Subtype of Ovarian Cancer via Regulation of Non-Canonical Wnt/PCP Pathway
To elucidate the functional roles of frizzled family receptor 7 (FZD7), researchers used an RNA interference gene knockdown approach in three Stem-A cell lines: CH1, PA1 and OV-17R. Si-FZD7 ovarian cancer cells showed reduced cell proliferation with an increase in the G0/G1 sub-population, with no effect on apoptosis. [Cell Death Dis] Full Article

Breast Cancer Stem Cells Rely on Fermentative Glycolysis and Are Sensitive to 2-Deoxyglucose Treatment
Researchers applied a proteomic and targeted metabolomic analysis in order to point out the main metabolic differences between breast cancer cells grown as spheres and thus enriched in cancer stem cells were compared with the same cells grown in adherent differentiating conditions. [Cell Death Dis] Full Article

Differentiation Therapy: Sesamin as an Effective Agent in Targeting Cancer Stem-Like Side Population Cells of Human Gallbladder Carcinoma
Sesamin, a food-derived agent, possesses anti-cancer activities both in vitro and in vivo. Investigators aimed to determine whether sesamin also have effects on cancer stem-like side population cells from gallbladder cancer. [BMC Complement Altern Med] Abstract | Full Article

Sox4 Links Tumor Suppression to Accelerated Aging in Mice by Modulating Stem Cell Activation
To specifically address a role for Sox4 in adult stem cells, scientists conditionally deleted Sox4 (Sox4cKO) in stratified epithelia. Sox4cKO mice show increased skin stem cell quiescence and resistance to chemical carcinogenesis concomitantly with downregulation of cell cycle, DNA repair, and activated hair follicle stem cell pathways. [Cell Rep] Full Article | Graphical Abstract | Press Release

Request Sample: ReLeSR™, Easy Passaging Through Selective Detachment of hPSCs

Helicobacter pylori Infection and Stem Cells at the Origin of Gastric Cancer
Helicobacter pylori infection is now recognized as the main and specific infectious cause of cancer in the world. It is responsible for gastric adenocarcinomas of both intestinal and diffuse types, which are the long-term consequences of the chronic infection of the gastric mucosa. [Oncogene] Abstract

Visit our reviews page to see a complete list of reviews in the cancer stem cell research field.

Synta Announces Advancement of Ganetespib into Phase III Extension of AML LI-1 Study for Patients with AML and High-Risk MDS
Synta Pharmaceuticals Corp. announced the advancement of ganetespib into the Phase III extension of the AML LI-1 trial. AML LI-1 is a multicenter, randomized Phase II/III clinical study evaluating several novel treatment regimens, including the combination of ganetespib with low dose cytarabine, in newly diagnosed elderly patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are not eligible for intensive chemotherapy. [Synta Pharmaceuticals Corp.] Press Release

U.S. Food and Drug Administration Approves Gilead’s Zydelig® (Idelalisib) for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma
Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has approved Zydelig® (idelalisib) 150 mg tablets for the treatment of three B-cell blood cancers. [Gilead Sciences, Inc.] Press Release

Aduro BioTech Receives Breakthrough Therapy Designation from FDA for Innovative Pancreatic Cancer Combination Immunotherapy
Aduro BioTech, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation for its pancreatic cancer combination treatment that consists of its CRS-207 and GVAX pancreas immunotherapies. [Aduro BioTech, Inc. (Business Wire)] Press Release

From our sponsor: Free mouse hematopoietic progenitors wallchart. Request your copy.

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW 14th International Conference Progress in Vaccination against Cancer (PIVAC-14)
September 24-26, 2014
Rome, Italy

Visit our events page to see a complete list of events in the cancer stem cell community.

NEW Technical Account Manager (GlobalStem)

Postdoctoral Position – Molecular Properties of Leukemic Stem Cells (BC Cancer Agency)

Product Marketing Manager (Cesca Therapeutics)

Postdoctoral Fellow – Genome Editing in Human Embryonic Stem Cells to Study Hereditary Cancer-Associated Mutations (UConn Health Center)

PhD Candidate – Mammary Stem Cell Biology (University of Amsterdam)

Postdoctoral Research Associate – Cancer Stem Cell Biology (University of California, San Diego)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Research Assistant/Research Associate – Stem Cell and Cancer Biology (University of North Texas Health Science Center)

Postdoctoral Fellow – Stem Cells and Cancer (Albert Einstein College of Medicine in New York)

Postdoctoral Fellow – Cancer and Stem Cell Biology (University of Pennsylvania)

Postdoctoral Fellowships – Cancer Research (German Cancer Research Center [DKFZ])

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Scientist – Immunology/Cell Separation (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Have we missed an important article or publication in Cancer Stem Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here

Learn more about Cancer Stem Cell News: Archives | Events | Contact Us